<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849459</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 02-0797</org_study_id>
    <secondary_id>MTS-GCO-02-0797</secondary_id>
    <secondary_id>NIH-0707-869</secondary_id>
    <secondary_id>CDR0000629819</secondary_id>
    <nct_id>NCT00849459</nct_id>
  </id_info>
  <brief_title>Gene Therapy in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max Sung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Placing the gene for interleukin-12 into breast cancer cells may help the body&#xD;
      build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of gene therapy in&#xD;
      treating women with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity and maximum tolerated dose of intratumoral injection of&#xD;
           adenovirus-mediated human interleukin-12 gene in women with metastatic breast cancer.&#xD;
&#xD;
        -  Determine the tumor response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the immune response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive a single dose of adenovirus-mediated human interleukin-12&#xD;
      intratumorally via percutaneous needle placement under ultrasound guidance.&#xD;
&#xD;
      Blood and tumor tissue samples are collected periodically for immunological laboratory&#xD;
      studies. Samples are analyzed for serum cytokine levels by ELISA; qualitative analysis of&#xD;
      immune biomarkers by IHC staining; and immune cell biomarker analysis by FACS.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Serum antibodies (titer) to adenovirus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity and safety</measure>
    <time_frame>up to 2 months</time_frame>
    <description>adverse events as assessed by NCI CTCAE v3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response progression)</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Sequential assessment of tumor on CT or MRI (complete response, partial response, stable disease, or disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Serum IL12, and IFNγ levels. Serum antibodies (titer) to adenovirus.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>adenovirus-mediated human interleukin-12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adenovirus-mediated human interleukin-12</intervention_name>
    <description>The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/&#xD;
1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC.</description>
    <arm_group_label>adenovirus-mediated human interleukin-12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic adenocarcinoma of the breast&#xD;
&#xD;
               -  Malignant disease in the skin, chest wall, or other sites (lymph nodes or primary&#xD;
                  tumor in the breast) accessible to percutaneous needle placement and injection&#xD;
&#xD;
                    -  Solitary or multiple tumors&#xD;
&#xD;
                    -  Measurable disease in ≥ 2 dimensions by physical examination or CT/MRI scan&#xD;
&#xD;
                    -  Malignant tumors in the skin and chest wall must be ≥ 4 mm in diameter by&#xD;
                       physical examination&#xD;
&#xD;
                    -  Malignant tumors in other accessible sites must be ≥ 1 cm in diameter on&#xD;
                       physical examination&#xD;
&#xD;
               -  Malignant disease in other organs (in addition to skin or chest wall metastases)&#xD;
                  allowed&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Life expectancy ≥ 16 weeks&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 mg/dL&#xD;
&#xD;
          -  PT normal&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 45 mL/min&#xD;
&#xD;
          -  Serum total bilirubin ≤ 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum transaminases ≤ 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Weight ≥ 30 kg (for patients treated with the highest dose level of study drug)&#xD;
&#xD;
          -  No active infection or concurrent serious medical illness&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No other malignancy within the past 5 years except for the following:&#xD;
&#xD;
               -  Inactive nonmelanoma skin cancer&#xD;
&#xD;
               -  In situ carcinoma of the cervix&#xD;
&#xD;
               -  Grade 1 papillary bladder cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No anticoagulant therapy with heparin or warfarin for ≥ 2 months after completion of&#xD;
             study treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max W. Sung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn Medical Center at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn Medical Center at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2009</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Max Sung</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

